Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05863325
What this trial is testing

Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 80
Large-scale testing (Phase 3)Looking for participantsNCT06350097
What this trial is testing

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 582
Large-scale testing (Phase 3)Study completedNCT00005838
What this trial is testing

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the LungAdenosquamous Cell Lung CancerLarge Cell Lung Cancer+3 more
National Cancer Institute (NCI) 756
Early research (Phase 1)Study completedNCT02300298
What this trial is testing

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 10
Testing effectiveness (Phase 2)Ended earlyNCT00093132
What this trial is testing

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

Who this might be right for
Carcinoma, Non-small Cell LungLung Cancer
Agennix 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04380636
What this trial is testing

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 870
Not applicableStudy completedNCT02910999
What this trial is testing

Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 868
Testing effectiveness (Phase 2)Looking for participantsNCT06627738
What this trial is testing

Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Centre Antoine Lacassagne 42
Testing effectiveness (Phase 2)UnknownNCT02367443
What this trial is testing

Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology Centre 92
Not applicableWithdrawnNCT03519958
What this trial is testing

Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca
Testing effectiveness (Phase 2)Looking for participantsNCT05384626
What this trial is testing

Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Who this might be right for
Locally Advanced Solid TumorMetastatic Solid Tumor
Nuvalent Inc. 840
Testing effectiveness (Phase 2)Study completedNCT02250326
What this trial is testing

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Celgene 240
Early research (Phase 1)Study completedNCT00857025
What this trial is testing

Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
City of Hope Medical Center 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305
Large-scale testing (Phase 3)Active Not RecruitingNCT05607550
What this trial is testing

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Who this might be right for
Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations
ArriVent BioPharma, Inc. 398
Testing effectiveness (Phase 2)Study completedNCT00006378
What this trial is testing

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Case Comprehensive Cancer Center 5
Large-scale testing (Phase 3)Study completedNCT04303780
What this trial is testing

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Who this might be right for
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Amgen 345
Testing effectiveness (Phase 2)UnknownNCT04606303
What this trial is testing

A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.

Who this might be right for
Locally Advanced NSCLC
Peking University Cancer Hospital & Institute 100
Testing effectiveness (Phase 2)Ended earlyNCT00749567
What this trial is testing

Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Hellenic Oncology Research Group 13
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Next Page